Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Second Quarter 2008 Results and Drug Development Programs
01 Agosto 2008 - 1:00PM
Business Wire
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the
development of a new class of small molecule compounds based on
endogenous steroid hormones, today announced that it will conduct a
conference call and live webcast on August 7, 2008 at 2:00 p.m. EDT
(11:00 a.m. PDT) to discuss its second quarter 2008 financial
results and to update its drug development programs in metabolic
disorders, inflammatory conditions and cancer. The Company will
release its financial results prior to the market opening that day.
The conference call can be accessed by dialing 800-237-9752
(domestic) or 617-847-8706 (international) and requesting the
Hollis-Eden conference call. A live webcast of the conference call
will be available under �Event Calendar� on the Investors section
of Hollis-Eden�s website at www.holliseden.com. The webcast will be
archived at the Company�s website for 30 days, and a replay of the
call will be available by phone for 24 hours beginning
approximately one hour after the call is completed, and can be
accessed at 888-286-8010 (domestic) or 617-801-6888
(international), passcode 30718006. About Hollis-Eden
Pharmaceuticals, Inc. Hollis-Eden Pharmaceuticals, Inc. is a world
leader in the development of a proprietary class of adrenal steroid
hormones as novel pharmaceuticals for human health. Through its
Hormonal Signaling Technology Platform, Hollis-Eden is developing a
new series of small molecule compounds that are metabolites or
synthetic analogs of endogenous hormones derived by the adrenal
glands from the body�s most abundant circulating adrenal steroid.
These steroid hormones, designed to restore the biological activity
of cellular signaling pathways disrupted by disease and aging, have
been demonstrated in humans to possess several properties with
potential therapeutic benefit -- they regulate innate and adaptive
immunity, reduce nonproductive inflammation and stimulate cell
proliferation. The Company�s clinical drug development candidates
include TRIOLEX� (HE3286), a next-generation compound currently in
clinical trials for the treatment of type 2 diabetes and ulcerative
colitis and being prepared for a clinical trial in rheumatoid
arthritis, and APOPTONE� (HE3235), a next-generation compound in a
clinical trial for late-stage prostate cancer. In addition to these
clinical development candidates, Hollis-Eden has an active research
program that is generating additional new clinical leads that are
being further evaluated in preclinical models of a number of
different diseases. For more information on Hollis-Eden, visit the
Company's website at www.holliseden.com. This press release
contains forward-looking statements within the meaning of the
federal securities laws concerning, among other things, the
potential and prospects of the Company's drug discovery program and
its drug candidates. Any statement included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause the Company's actual results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. Such statements are subject to certain
risks and uncertainties inherent in the Company�s business,
including, but not limited to: the ability to complete preclinical
and clinical trials successfully and within specified timelines, if
at all; the ability to obtain regulatory approval for TRIOLEX
(HE3286), APOPTONE (HE3235) or any other investigational drug
candidate; the Company's future capital needs; the Company's
ability to obtain additional funding; the ability of the Company to
protect its intellectual property rights and to not infringe the
intellectual property rights of others; the development of
competitive products by other companies; and other risks detailed
from time to time in the Company's filings with the Securities and
Exchange Commission. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Except as required by law, the Company undertakes no obligation to
update or revise the information contained in this press release as
a result of new information, future events or circumstances arising
after the date of this press release.
Grafico Azioni Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Hollis-Eden Pharmaceuticals (MM) (NASDAQ): 0 articoli recenti
Più Hollis-Eden Pharmaceuticals, Inc. Articoli Notizie